Stifel Nicolaus Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price

Arvinas (NASDAQ:ARVN - Free Report) had its price objective reduced by Stifel Nicolaus from $63.00 to $51.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also recently issued reports on ARVN. BMO Capital Markets reduced their price objective on Arvinas from $90.00 to $88.00 and set an "outperform" rating for the company in a report on Wednesday, November 20th. Guggenheim restated a "buy" rating on shares of Arvinas in a report on Thursday, December 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Wedbush reiterated an "outperform" rating and issued a $57.00 price target on shares of Arvinas in a research note on Tuesday. Finally, Barclays cut their price target on Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $60.00.

Arvinas Stock Up 3.6 %

Shares of NASDAQ:ARVN traded up $0.64 during midday trading on Wednesday, reaching $18.31. The company had a trading volume of 935,305 shares, compared to its average volume of 823,758. The business's 50 day moving average price is $18.88 and its 200 day moving average price is $23.22. The stock has a market cap of $1.26 billion, a PE ratio of -3.92 and a beta of 1.88. Arvinas has a 1-year low of $16.61 and a 1-year high of $53.08.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. During the same period in the prior year, the firm posted ($2.53) EPS. On average, research analysts expect that Arvinas will post -3.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arvinas

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Arvinas during the 3rd quarter worth approximately $39,000. KBC Group NV boosted its holdings in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after buying an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock worth $61,000 after buying an additional 440 shares during the period. Quantbot Technologies LP boosted its holdings in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after purchasing an additional 2,601 shares during the period. Finally, Exchange Traded Concepts LLC boosted its holdings in Arvinas by 37.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $164,000 after purchasing an additional 1,798 shares during the period. Hedge funds and other institutional investors own 95.19% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.